Antithrombotische Therapie in der Schwangerschaft^[*]

• Literatur

• 1 Lockwood CJ. Inherited thrombophilias in pregnant patients: detection and treatment paradigm. Obstet Gynecol 2002; 99: 333-341
• 2 Ku DH, Arkel YS, Paidas MP et al. Circulating levels of inflammatory cytokines (IL-1 beta and TNF-alpha), resistance to activated protein C, thrombin and fibrin generation in uncomplicated pregnancies. Thromb Haemost 2003; 90: 1074-1079
• 3 Lurie S, Rigini N, Zabeeda D et al. Changes in platelet function, volume and count during labor and 24 hours postpartum. Platelets 2003; 14: 355-358
• 4 Duhl AJ, Paidas MJ, Ural SH et al. Antithrombotic therapy and pregnancy: consensus report and recommendations for prevention and treatment of venous thromboembolism and adverse pregnancy outcomes. Am J Obstet Gynecol 2007; 197: 457.e1-457.e21
• 5 Schaefer C, Hannemann D, Meister R et al. Vitamin K antagonists and pregnancy outcome. A multi-centre prospective study. Thromb Haemost 2006; 95: 949-957
• 6 Regitz-Zagrosek V, Blomstrom Lundqvist C, Borghi C et al. ESC Guidelines on the management of cardiovascular diseases during pregnancy: the Task Force on the Management of Cardiovascular Diseases during Pregnancy of the European Society of Cardiology (ESC). Eur Heart J 2011; 32: 3147-3197
• 7 Sillesen M, Hjortdal V, Vejlstrup N et al. Pregnancy with prosthetic heart valves – 30 yearsʼ nationwide experience in Denmark. Eur J Cardiothorac Surg 2011; 40: 448-454
• 8 Vitale N, De Feo M, De Santo LS et al. Dose-dependent fetal complications of warfarin in pregnant women with mechanical heart valves. J Am Coll Cardiol 1999; 33: 1637-1641
• 9 Vahanian A, Alfieri O, Andreotti F et al. Joint Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology (ESC); European Association for Cardio-Thoracic Surgery (EACTS). Guidelines on the management of valvular heart disease (version 2012). Eur Heart J 2012; 33: 2451-2496
• 10 Chan WS, Anand S, Ginsberg JS. Anticoagulation of pregnant women with mechanical heart valves: a systematic review of the literature. Arch Intern Med 2000; 160: 191-196
• 11 Abildgaard U, Sandset PM, Hammerstrom J et al. Management of pregnant women with mechanical heart valve prosthesis: thromboprophylaxis with low molecular weight heparin. Thromb Res 2009; 124: 262-267
• 12 Hering D, Horstkotte D. [Use of low-molecular-weight heparins in patients with prosthetic heart valves]. Dtsch Med Wochenschr 2003; 128: 1129-1133
• 13 Van de Werf F, Brueckmann M, Connolly SJ et al. A comparison of dabigatran etexilate with warfarin in patients with mechanical heart valves: The randomized phase II study to evaluate the safety and pharmacokinetics of oral dabigatran etexilate in patients after heart valve replacement (RE-ALIGN). Am Heart J 2012; 163: 931.e1-937.e1
• 14 Bauersachs RM, Dudenhausen J, Faridi A et al. Risk stratification and heparin prophylaxis to prevent venous thromboembolism in pregnant women. Thromb Haemost 2007; 98: 1237-1245
• 15 Greer IA, Nelson-Piercy C. Low-molecular-weight heparins for thromboprophylaxis and treatment of venous thromboembolism in pregnancy: a systematic review of safety and efficacy. Blood 2005; 106: 401-407
• 16 Ladner HE, Danielsen B, Gilbert WM. Acute myocardial infarction in pregnancy and the puerperium: a population-based study. Obstet Gynecol 2005; 105: 480-484